Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole

BMC Pharmacology

Volumn 10, Issue , 2010, Pages

  Ferrari Toninelli, Giulia ^a   Maccarinelli, Giuseppina ^a   Uberti, Daniela ^a   Buerger, Erich ^b   Memo, Maurizio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR; HYDROGEN PEROXIDE; PRAMIPEXOLE; REACTIVE OXYGEN METABOLITE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIOXIDANT; BENZOTHIAZOLE DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; PRAMIPEXOL; ROSIGLITAZONE;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENANTIOMER; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; ISOMER; MITOCHONDRION; NEUROBLASTOMA CELL; NEUROPROTECTION; APOPTOSIS; CELL SURVIVAL; CULTURE TECHNIQUE; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM; NERVE CELL; OXIDATIVE STRESS; PATHOLOGY; TUMOR CELL CULTURE;

ANTIOXIDANTS; APOPTOSIS; BENZOTHIAZOLES; CELL CULTURE TECHNIQUES; CELL SURVIVAL; DOPAMINE ANTAGONISTS; DRUG DELIVERY SYSTEMS; HUMANS; HYDROGEN PEROXIDE; MITOCHONDRIA; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; THIAZOLIDINEDIONES; TUMOR CELLS, CULTURED;

EID: 77649123090     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-10-2     Document Type: Article

References (30)

1. Davie CA. A review of Parkinson's disease. Br Med Bull 2008, 86:109-127. 10.1093/bmb/ldn013, 18398010.
2. McKeith IG, Mosimann UP. Dementia with Lewy bodies and Parkinson's disease. Parkinsonism and Related Disorders 2004, 10:S15-S18. 10.1016/j.parkreldis.2003.12.005, 15109582.
3. Adams JD, Odunze IN. Oxygen free radicals and Parkinson's disease. Free Radic Biol Med 1991, 10:161-169. 10.1016/0891-5849(91)90009-R, 2016074.
4. Olanow CW. A radical hypothesis for neurodegeneration. Trends Neurosci 1993, 16:439-444. 10.1016/0166-2236(93)90070-3, 7507613.
5. Schapira AH. Neuroprotection in PD - a role for dopamine agonists?. Neurology 2003, 61:S34-S42.
6. Jenner P. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Curr Opin Neurol 2003, 16:S3-S7. 10.1097/00019052-200312001-00002, 15180131.
7. Ferrari-Toninelli G, Bonini SA, Cenini G, Maccarinelli G, Grilli M, Uberti D, Memo M. Dopamine receptor agonists for protection and repair in Parkinson's disease. Curr Top Med Chem 2008, 8:1089-1099. 10.2174/156802608785161402, 18691134.
8. Radad K, Gille G, Rausch WD. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol Rep 2005, 57(6):701-712.
9. Gassen M, Glinka Y, Pinchasi B, Youdim MB. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol 1996, 308(2):219-225. 10.1016/0014-2999(96)00291-9, 8840135.
10. Kondo T, Ito T, Sugita Y. Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum. Ann NY Acad Sci 1994, 738:222-229.
11. Ogawa N, Tanaka K, Asanuma M, Kawai M, Masumizu T, Kohno M, Mori A. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 1994, 657:207-213. 10.1016/0006-8993(94)90969-5, 7820619.
12. Takashima H, Tsujihata M, Kishikawa M, Freed WJ. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors. Exp Neurol 1999, 159:98-104. 10.1006/exnr.1999.7122, 10486178.
13. Ferger B, Teismann P, Mierau J. The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study. Brain Res 2000, 883:216-223. 10.1016/S0006-8993(00)02929-2, 11074050.
14. Uberti D, Carsana T, Francisconi S, Ferrari-Toninelli G, Canonico PL, Memo M. A novel mechanism for pergolide-induced neuroprotection: inhibition of NF-kappaB nuclear translocation. Biochem Pharmacol 2004, 67:1743-1750. 10.1016/j.bcp.2004.01.012, 15081873.
15. Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 1999, 838:51-59. 10.1016/S0006-8993(99)01688-1, 10446316.
16. Tanaka K, Miyazaki I, Fujita N, Haque ME, Asanuma M, Ogawa N. Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist. Neurochem Res 2001, 26:31-36. 10.1023/A:1007672414239, 11358279.
17. Uberti D, Bianchi I, Olivari L, Ferrari-Toninelli G, Bonini SA, Memo M. Dopaminergic agonists: possibile neurorescue drugs endowed with independent and synergistic multisites of action. Neurochem Res 2007, 32:1726-1729. 10.1007/s11064-007-9350-9, 17486445.
18. Le WD, Jankovic J, Xie W, Appel SH. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm 2000, 107:1165-73. 10.1007/s007020070030, 11129106.
19. Abramova NA, Cassarino DS, Khan SM, Painter TW, Bennett JP. Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J Neurosci Res 2002, 67:494-500. 10.1002/jnr.10127, 11835316.
20. Fujita Y, Izawa Y, Ali N, Kanematsu Y, Tsuchiya K, Hamano S, Tamaki T, Yoshizumi M. Pramipexole protects against H2O2-induced PC12 cell death. Naunyn Schmiedebergs Arch Pharmacol 2006, 372:257-66. 10.1007/s00210-005-0025-2, 16362428.
21. Iravani MM, Sadeghian M, Leung CC, Tel BC, Rose S, Shapira AH, Jenner P. Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response. Exp Neurol 2008, 212:522-531. 10.1016/j.expneurol.2008.04.037, 18571649.
22. Uberti D, Bianchi I, Olivari L, Ferrari-Toninelli G, Canonico P, Memo M. Pramipexole prevents neurotoxicity induced by oligomers of beta-amyloid. Eur J Pharmacol 2007, 569(3):194-196. 10.1016/j.ejphar.2007.05.009, 17572405.
23. Cassarino DS, Fall CP, Smith TS, Bennett JP. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem 1998, 71:295-301.
24. Danzeisen R, Schwalenstoecker B, Gillardon F, Buerger E, Krzykalla V, Klinder K, Schild L, Hengerer B, Ludolph AC, Dorner-Ciossek C, Kussmaul L. Targeted antioxidant and neuroprotective properties of the dopamine agonist pramipexole and ist nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-L-propylamino-benzathiazole Dihydrochloride]. J Pharmacol Exp Ther 2006, 316:189-199. 10.1124/jpet.105.092312, 16188953.
25. Sayeed I, Parvez S, Winkler-Stuck K, Seitz G, Trieu I, Wallesch CW, Schönfeld P, Siemen D. Patch clamp reveals powerful blockade of the mitochondrial permeability transition pore by the D2-receptor agonist pramipexole. FASEB J 2006, 20(3):556-8.
26. Gribkoff VK, Bozik ME. KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzohiazole-diamine dihydrochloride monohydrate] for the treatment of Amyotrphic Lateral Sclerosis. CNS Neuroscience & Ther 2008, 14:215-226.
27. Gu M, Iravani M, Cooper JM, Jenner P, Shapira AHV. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem 2004, 91:1075-1081. 10.1111/j.1471-4159.2004.02804.x, 15569251.
28. Koopman WJH, Verkaart S, van Emst-de Vries SE, Grefte S, Smeitink JAM, Willems PHGM. Simultaneous quantification of oxidative stress and cell spreading using 5-(and 6-)-chloromethyl-2'-7'-dichlorofluorescein. Cytometry Part A 2006, 69A:1184-1192.
29. Gomes A, Fernandes E, Lima JLFC. Fluorescence probes used for detection of reactive oxygen species. J Biochem Biophys Methods 2005, 65:45-80. 10.1016/j.jbbm.2005.10.003, 16297980.
30. Swift LM, Sarvazyan N. Localization of dichlorofluorescein in cardiac myocytes: Implications for assessment of oxidative stress. Am J Physiol Heart Circ Physiol 2000, 278:H982-H990.